Total Practice Management, LLC — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$24,900	692
2024	Research	$63,864	15
2023	Research	$39,169	14
2022	Research	$21,780	1
2021	Research	$21,780	1

Breakdown

Who paid Research payments · program years 2021–2025

Glaukos Corporation $63,450 14 payments
Ocular Therapeutix, Inc. $54,920 3 payments
Astellas Pharma Global Development $28,223 14 payments
NotalVision $24,900 692 payments

Studies the money was for Research payments · program years 2021–2025

Multicenter, Randomized, Double-Masked, Active-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of Travoprost Ophthalmic Topical Cream in Subjects with Open-angle Glaucoma or Ocular Hypertension $63,450 14 payments
DEXENZA compared to sham dilation plus topical steroid therapy prior to cataract surgery in patients who receive premium IOLs $33,140 2 payments
Nrich $24,900 692 payments
DEXTENZA compared to sham dilation plus topical steroid therapy in patietns who receive premium intraocular lenses $21,780 1 payment
A Phase 3 Multicenter, Randomized, Double Masked, Sham-Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients with Geographic Atropy Secondary to Age-Related Macular Degeneration $18,393 4 payments
An Open-Label Extension (OLE) Phase 3 Trial to Assess the Safety of Intravitreal Administration of Avacincaptad Pegol (Complement C5 Inhibitor) in Patients with Geographic Atrophy who Previously Completed Phase 3 Study ISEE2008 (GATHER2) $9,830 10 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.